Epilepsy

Epilepsy is characterized by a long-term tendency to experience recurrent, unprovoked seizures. Seizures According to the 2025 classification by the International League Against Epilepsy (ILAE), seizures are grouped into four main classes: focal, generalized, unknown (whether focal or generalized), and unclassified. Focal seizures Focal seizures originate in one area of the brain and may involve localized or distributed networks. Muscle jerks may start in a specific muscle group and spread to surrounding muscle groups, a pattern known as a Jacksonian march. Automatisms, or non-consciously generated activities, may occur; these may be simple repetitive movements like smacking the lips or more complex activities such as attempts to pick up something. This form of seizure (whether focal to bilateral, generalized, or of unknown onset) is associated with the highest risk of injury, medical complications, and sudden unexpected death in epilepsy (SUDEP). They can cause falls and injury. A small subset of individuals have reflex epilepsy, in which seizures are reliably provoked by specific stimuli. These reflex seizures account for about 6% of epilepsy cases. Common triggers include flashing lights (photosensitive epilepsy), sudden sounds, or specific cognitive tasks such as reading or performing calculations. In some epilepsy syndromes, seizures occur more frequently during sleep or upon awakening. Seizure clusters Seizure clusters are multiple seizures occurring over a short period of time, with incomplete recovery between events. They are distinct from status epilepticus, though the two may overlap. Definitions vary across studies, but seizure clusters are typically described as two or more seizures within 24 hours or a noticeable increase in seizure frequency over a person's usual baseline. Estimates of their prevalence range widely (from 5% to 50% of people with epilepsy) largely due to differing definitions and populations studied. Seizure clusters are more common in individuals with drug-resistant epilepsy, high baseline seizure frequency, or certain epilepsy syndromes. They are associated with increased emergency care utilization, worse quality of life, impaired psychosocial functioning, and possibly elevated risk of mortality. Postictal state After the active portion of a seizure (the ictal state) there is typically a period of recovery during which there is confusion, referred to as the postictal state, before a normal level of consciousness returns, lasting minutes to days. Postictal psychosis occurs in approximately 2% of individuals with epilepsy, particularly after clusters of generalized tonic–clonic seizures. Psychosocial Epilepsy can have substantial effects on psychological and social well-being. People with the condition may experience social isolation, stigma, or functional disability, which can contribute to lower educational attainment and reduced employment opportunities. These challenges often extend to family members, who may also encounter stigma and increased caregiving burden. Several psychiatric and neurodevelopmental disorders are more common in individuals with epilepsy. These include depression, anxiety, obsessive–compulsive disorder (OCD), and migraine. Attention deficit hyperactivity disorder (ADHD) is particularly prevalent among children with epilepsy, occurring three to five times more often than in the general population. ADHD and epilepsy together can markedly affect behavior, learning, and social development. Epilepsy is also more common in children with autism spectrum disorder. Approximately, one-in-three people with epilepsy have a lifetime history of a psychiatric disorder. This association is thought to reflect a combination of shared neurobiological mechanisms and the psychosocial impact of living with a chronic neurological condition. Some research also suggests that psychiatric conditions such as depression may precede the onset of epilepsy in certain individuals, particularly those with focal epilepsy. The nature of this association remains under investigation and may involve shared pathways, diagnostic overlap, or other confounding factors. Comorbid depression and anxiety are associated with poorer quality of life, increased healthcare utilization, reduced treatment response (including to surgery), and higher mortality. Some studies suggest that these psychiatric conditions may influence quality of life more than seizure type or frequency. Despite their clinical importance, depression and anxiety often go underdiagnosed and undertreated in people with epilepsy. == Causes ==

Epilepsy can result from a wide range of genetic and acquired factors, and in many cases, both play a role. Acquired causes include serious traumatic brain injury, stroke, brain tumors, and central nervous system infections. Despite advances in diagnostic tools, no clear cause is identified in approximately 50% of cases. These are known as acute symptomatic seizures and are distinct from epilepsy, which involves a recurrent tendency to have unprovoked seizures over time. The International League Against Epilepsy (ILAE) classifies the causes of epilepsy into six broad categories: structural, genetic, infectious, metabolic, immune, and unknown. These categories are not mutually exclusive, and more than one may apply in an individual case. Structural Structural causes of epilepsy refer to abnormalities in the anatomy of the brain that increase the risk of seizures. These may be acquired (such as from a stroke, traumatic brain injury, brain tumor, or central nervous system infection) or developmental and genetic in origin, as seen in conditions like focal cortical dysplasia or certain congenital brain malformations. A major example is mesial temporal sclerosis (MTS), a common cause of temporal lobe epilepsy. Traumatic brain injury is estimated to cause between 6% and 20% of epilepsy cases, depending on severity, mechanism, and study population. Mild brain injury increases the risk about two-fold, while severe brain injury increases the risk seven-fold. In those who have experienced a high-powered gunshot wound to the head, the risk is about 50%. Stroke is a major cause of epilepsy, particularly in older adults. Approximately 6% to 10% of individuals who experience a stroke develop epilepsy, most often within the first few years after the event. The risk is highest following severe strokes that involve cortical regions, especially in cases of intracerebral hemorrhage. Brain tumors are implicated in approximately 4% of epilepsy cases, with seizures occurring in nearly 30% of individuals with intracranial neoplasms. Around 1–2% of cases are caused by a single gene defect, while most are due to a combination of multiple genes and environmental influences. More recent exome and genome sequencing studies have begun to reveal a number of de novo mutations that are responsible for some epileptic encephalopathies, including CHD2 and SYNGAP1 and DNM1, GABBR2, FASN and RYR3. Some genetic disorders, including phakomatoses such as tuberous sclerosis complex and Sturge–Weber syndrome are strongly associated with epilepsy. Infectious Infectious causes include infections of the central nervous system that directly affect brain tissue and lead to long-term seizure susceptibility. Metabolic Metabolic causes of epilepsy include metabolic disorders that disrupt the brain's normal function. In rare cases, epilepsy may result from inborn errors of metabolism, such as porphyria, mitochondrial diseases, urea cycle disorders or glucose transporter type 1 (GLUT1) deficiency. These often present early in life and may be associated with developmental delays, movement disorders and other neurological symptoms. Some forms of malnutrition, particularly in low- and middle-income countries, have been associated with a higher risk of epilepsy, although it remains unclear whether the relationship is causal or due to other contributing factors. Unknown Unknown causes of epilepsy are cases where no clear structural, genetic, infectious, immune or metabolic origin can be identified despite thorough evaluation. A substantial proportion of epilepsy cases still fall into this group, particularly in regions with limited access to advanced testing. == Mechanism ==

Understanding the mechanism of epilepsy involves two related but distinct questions: how the brain develops a long-term tendency to generate seizures (epileptogenesis), and how individual seizures begin and spread (ictogenesis). While these processes are not yet fully understood, research has identified a number of cellular, molecular, and network-level changes that contribute to each. Seizures In a healthy brain, neurons communicate through electrical signals that are generally desynchronized. This activity is tightly regulated by a balance between excitatory and inhibitory influences. Intracellular factors that influence neuronal excitability include the type, number, and distribution of ion channels, as well as alterations in receptor function and gene expression. Extracellular factors include ionic concentrations in the surrounding environment, synaptic plasticity, and the regulation of neurotransmitter breakdown by glial cells. During a seizure, this balance breaks down, leading to a sudden and excessive synchronization of neuronal firing. A localized group of neurons may begin firing together in an abnormal and repetitive pattern, overwhelming normal inhibitory controls. This abnormal activity can remain confined to a specific region of the brain or propagate to other areas. The process by which this transition occurs is known as ictogenesis. It involves a shift in network dynamics, typically beginning with excessive excitatory activity in a susceptible area of cortex (known as a seizure focus) and failure of inhibitory mechanisms to contain it. At the cellular level, ictogenesis is often marked by a paroxysmal depolarizing shift, a characteristic pattern of sustained neuronal depolarization followed by rapid repetitive firing. As excitatory feedback loops engage and inhibition further declines, the seizure may become self-sustaining and spread to other regions of the brain. There is evidence that epileptic seizures are usually not a random event. Seizures are often brought on by factors (also known as triggers) such as stress, excessive alcohol use, flickering light, lack of sleep, among others. The term seizure threshold is used to indicate the amount of stimulus necessary to bring about a seizure; this threshold is lowered in epilepsy. The seizures can be described on different scales, from the cellular level to the whole brain. Epilepsy Epileptogenesis is the sequence of biological events that transforms a previously non-epileptic brain into one capable of producing spontaneous seizures. It can occur after a wide range of brain insults, including traumatic brain injury, stroke, central nervous system infections, brain tumors, or prolonged seizures (such as status epilepticus). In most cases, no clear cause is identified. Although not fully understood, it involves a range of biological changes, including neuronal loss, synaptic reorganization, gliosis, neuroinflammation, and disruption of the blood-brain barrier. Together, these changes contribute to the formation of hyperexcitable neural networks, often anchored around a seizure focus. Once established, this pathological network increases the brain's susceptibility to seizures, even in the absence of ongoing injury. ==Diagnosis==

The diagnosis of epilepsy is primarily clinical, based on a thorough evaluation of the person's history, seizure features, and risk of recurrence. Diagnostic tests such as electroencephalograms and neuroimaging can support the diagnosis. Clinicians must also distinguish epileptic seizures from other conditions that can mimic them and determine whether the event was provoked by an acute, reversible cause or if it suggests a long-term tendency for unprovoked seizures. Definition According to the International League Against Epilepsy (ILAE), a diagnosis of epilepsy can be made when any one of the following criteria is met: Earlier systems emphasized seizure location and used terms such as "partial" or "cryptogenic," which have been replaced in the modern framework. The current system, introduced in 2017, was proposed to reflect advances in neuroimaging, genetics, and in the clinical understanding of the condition. Syndromes An epilepsy syndrome is a specific diagnosis based on a combination of features, including seizure types, age of onset, EEG patterns, imaging findings, and associated symptoms or comorbidities. In many cases, a known genetic or structural cause may also support the diagnosis. Some syndromes are self-limited and age-dependent, such as childhood absence epilepsy, juvenile myoclonic epilepsy, and self-limited epilepsy with centrotemporal spikes, These include Lennox–Gastaut syndrome, West syndrome, Rasmussen syndrome and Dravet syndrome, which typically present in early childhood with drug-resistant seizures and are associated with significant neurodevelopmental impairments. Some epilepsy syndromes do not yet fit neatly within current etiological categories, particularly when no definitive cause has been identified. In many cases, a genetic cause is presumed based on age of onset, family history, and electroclinical features, even if no mutation has been found. Following clinical evaluation, selected tests may be used to rule out acute causes and seizure mimics. A 12-lead electrocardiogram (ECG) is recommended for all individuals presenting with a first seizure, to screen for cardiac arrhythmias and other cardiovascular conditions that may resemble epilepsy. Blood tests may be performed to identify metabolic disturbances such as hypoglycemia, electrolyte imbalances, or renal and hepatic dysfunction, particularly in acute settings. Once epilepsy is suspected, electroencephalography (EEG) is used to support the diagnosis. A routine EEG may include activation techniques such as hyperventilation or photic stimulation. However, a normal EEG does not rule out epilepsy. When initial EEG findings are inconclusive, prolonged monitoring techniques such as ambulatory or video EEG may be necessary, including sleep-deprived recordings. Differential diagnosis Several conditions can resemble epileptic seizures and are collectively referred to as non-epileptic seizures. Common mimics include fainting (syncope), psychogenic non-epileptic seizures (PNES), transient ischemic attacks, migraine, narcolepsy, and various sleep or movement disorders. In children, events such as reflux, breath-holding spells, parasomnias and others may resemble seizures. Differentiating between the two can be difficult and often requires prolonged video EEG monitoring. ==Prevention==

Although many causes of epilepsy are not preventable, several known risk factors are modifiable. Perinatal care can lower the risk of epilepsy in infants. == Complications ==

Epilepsy can lead to a range of medical, psychological, and social complications, particularly when seizures are frequent or uncontrolled. The risk of drowning is significantly increased in people with epilepsy, especially those with poor seizure control. People with epilepsy are at greater risk for mental health conditions, including depression, anxiety, and social isolation. These challenges are often compounded by stigma, employment difficulties, and driving restrictions. In children, epilepsy, especially when drug-resistant, can interfere with cognitive development and academic performance. A rare but serious complication is sudden unexpected death in epilepsy (SUDEP), which is most often associated with uncontrolled generalized tonic–clonic seizures, particularly during sleep. ==Management==

The primary goals of epilepsy management are to control seizures, minimize treatment side effects, and optimize quality of life. Management strategies are individualized based on the type of seizures or epilepsy syndrome, the underlying cause when known, the person's age and comorbidities, and their preferences and life circumstances. In drug-resistant cases, different management options may be considered, including special diets, the implantation of a neurostimulator, or neurosurgery. • Stay calm and remove any potential hazards from the area. Clear the space of sharp objects, furniture, or anything that might cause injury. • If the person is standing, gently guide them to the ground to avoid a fall. • Position the person on their side and into the recovery position, which helps keep the airway clear and reduces the risk of choking. If possible, place something soft (e.g., a jacket or cushion) under their head to prevent injury. • Do not restrain their movements or attempt to hold them down. Do not put anything in their mouth, as this may cause harm. Convulsive status epilepticus requires immediate medical attention to prevent serious complications. In a community setting (such as at home or in the ambulance), first-line treatment includes the administration of benzodiazepines. If the person has an individualized emergency management plan, which may have been developed with healthcare providers and outlines personalized treatment steps (such as the use of buccal midazolam or rectal diazepam), this plan should be followed immediately. Controlled release carbamazepine appears to work as well as immediate release carbamazepine, and may have fewer side effects. In the UK, carbamazepine or lamotrigine are recommended as first-line treatments for focal seizures, with levetiracetam and valproate used as second-line treatments due to concerns about cost and side effects. Valproate is the first-line choice for generalized seizures, while lamotrigine is used as second-line. For absence seizures, ethosuximide or valproate are recommended, with valproate also being effective for myoclonic and tonic–clonic seizures. Controlled-release formulations of carbamazepine may be preferred in some cases, as they appear to be equally effective as immediate-release carbamazepine but may have fewer side effects. Once a person's seizures are well-controlled on a specific treatment, it is generally not necessary to routinely check medication blood levels, unless there are concerns about side effects or toxicity. Access, however, may be difficult as some countries label it as a controlled drug. Many of the common used medications, such as valproate, phenytoin, carbamazepine, phenobarbital, and gabapentin have been reported to cause increased risk of birth defects, especially when used during the first trimester. Among the antiepileptic medications, levetiracetam and lamotrigine seem to carry the lowest risk of causing birth defects. Stopping is possible in about 70% of children and 60% of adults. Surgery Epilepsy surgery is a treatment option for individuals with drug-resistant epilepsy, typically defined as the failure of at least two appropriately chosen and tolerated antiseizure medications. Surgery is most effective in cases of focal epilepsy, where seizures originate from a specific area of the brain that can be safely removed. Epilepsy surgery remains underutilized worldwide and is often reserved for individuals whose condition has reached an advanced or chronic stage. The primary goal of epilepsy surgery is to achieve seizure freedom, but even when that is not possible, palliative procedures that significantly reduce seizure frequency can lead to meaningful improvements in quality of life and development, particularly in children. Studies suggest that 60-70% of individuals with drug-resistant focal epilepsy experience a substantial reduction in seizures following surgery. Common procedures include anterior temporal lobe resection, which often involves removal of the hippocampus in cases of mesial temporal lobe epilepsy, as well as lesionectomy for tumors or cortical dysplasia, and lobectomy for larger seizure foci. In many cases, antiseizure medications can be tapered following successful surgery, though long-term monitoring remains essential. Neuromodulation Neurotherapy or Neuromodulation therapies, including vagus nerve stimulation (VNS), deep brain stimulation (DBS), Neuromodulation through Radiotherapy (e.g. Leksell Gamma Knife) and responsive neurostimulation (RNS), are treatment options for individuals with drug-resistant epilepsy who are not candidates for resective surgery, or for whom previous surgery has not resulted in seizure freedom. These neurotherapies aim to reduce seizure frequency and severity by delivering controlled electrical stimulation to targeted neural circuits. Diet Dietary therapy, particularly the ketogenic diet (high-fat, low-carbohydrate, adequate-protein), is a non-pharmacological treatment option used primarily in children with drug-resistant epilepsy. Evidence suggests that children on a classical ketogenic diet may be up to three times more likely to achieve seizure freedom and up to six times more likely to experience a ≥50% reduction in seizure frequency compared to those receiving standard care. Modified versions of the diet, such as the modified Atkins diet, are better tolerated but may be less effective. In adults, the ketogenic diet has shown limited evidence of achieving seizure freedom, though it may increase the likelihood of seizure reduction. However, further research is necessary. The diet leads to an increased elevation of plasma decanoic acid and ketones. However, some research is giving the indication that it may be the decanoic acid that is anti-convulsant. A gluten-free diet has been proposed in rare cases of epilepsy associated with celiac disease and occipital calcifications, though evidence is limited and based on small case series. These approaches may improve quality of life, emotional wellbeing, and treatment adherence; however, evidences targeting seizure control are uncertain. Avoidance therapy consists of minimizing or eliminating triggers. For example, those who are sensitive to light may have success with using a small television, avoiding video games, or wearing dark glasses. Biofeedback, particularly EEG-based operant conditioning, has shown preliminary benefit in some people with drug-resistant epilepsy. However, these methods are considered adjunctive and are not recommended as standalone treatments. Cannabidiol (CBD) has shown benefit as an add-on therapy in certain severe childhood epilepsies. A purified form of CBD was approved by the U.S. FDA in 2018 and by the European Medicines Agency (EMA) in 2020 for the treatment of Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex. Regular physical activity is generally considered safe and may have beneficial effects on seizure frequency, mood, and overall wellbeing. While evidence remains limited, some studies suggest that moderate exercise can reduce seizure burden in certain individuals. Seizure response dogs have been trained to assist individuals during or after seizures by providing physical support or alerting others. Although anecdotal reports claim that some dogs can anticipate seizures, there is no conclusive scientific evidence supporting the consistent ability of dogs to predict seizures before they occur. Various forms of alternative medicine, including acupuncture, routine vitamins, and yoga, have no reliable evidence to support their use in epilepsy. Melatonin, , is insufficiently supported by evidence. The trials were of poor methodological quality and it was not possible to draw any definitive conclusions. == Contraception and pregnancy ==

Women with epilepsy may experience a temporary increase in seizure frequency when they begin hormonal contraception. Some anti-seizure medications interact with enzymes in the liver and cause the drugs in hormonal contraception to be broken down more quickly. These enzyme inducing drugs make hormonal contraception less effective, and this is particularly hazardous if the anti-seizure medication is associated with birth defects. Potent enzyme-inducing anti-seizure medications include carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide. The drugs perampanel and topiramate can be enzyme-inducing at higher doses. Conversely, hormonal contraception can lower the amount of the anti-seizure medication lamotrigine circulating in the body, making it less effective. Pregnancy does not seem to change seizure frequency very much. When seizures happen, however, they can cause some pregnancy complications, such as pre-term births or the babies being smaller than usual when they are born. Some anti-seizure drugs significantly increase the risk of birth defects and intrauterine growth restriction, as well as developmental, neurocognitive, and behavioral disorders. Most women with epilepsy receive safe and effective treatment and have typical, healthy children. The highest risks are associated with specific anti-seizure drugs, such as valproic acid and carbamazepine, and with higher doses. Folic acid supplementation, such as through prenatal vitamins, reduced the risk. Planning pregnancies in advance gives women with epilepsy an opportunity to switch to a lower-risk treatment program and reduced drug doses. Although anti-seizure drugs can be found in breast milk, women with epilepsy can breastfeed their babies, and the benefits usually outweigh the risks. ==Prognosis==

Epilepsy is generally considered a chronic neurological condition. Its long-term course can vary widely depending on factors such as seizure type, underlying cause, and response to treatment. Although epilepsy is not typically "cured," in many cases it may be considered resolved. According to the ILAE, epilepsy is considered to be resolved in individuals who have been seizure-free for at least 10 years, with no antiseizure medications for the last 5 of those years. Epilepsy disproportionately affects low- and middle-income countries, where nearly 80% of the global epilepsy population resides. In these countries, to 75% of individuals with epilepsy do not receive the treatment they need. This is because observed cognitive decline could be a result of the cause of the epilepsy (e.g. epilepsy caused by mesial temporal sclerosis), or be secondary to the epilepsy (e.g. brain damage from falling due to a seizure, or impairment from pharmacological or surgical treatment of the epilepsy). The greatest increase in mortality from epilepsy is among the elderly. Death from status epilepticus is primarily due to an underlying problem rather than missing doses of medications. the cause of this is unclear. and accounts for about 15% of epilepsy-related deaths; it is unclear how to decrease its risk. In the United Kingdom, it is estimated that 40–60% of deaths are possibly preventable. In the developing world, many deaths are due to untreated epilepsy leading to falls or status epilepticus. ==Epidemiology==

Epilepsy is one of the most common serious neurological disorders, affecting approximately 50 million people globally as of 2021, with the majority living in low- and middle-income countries. The point prevalence of active epilepsy is generally reported between 5 and 7 per 1,000 people, while lifetime prevalence is slightly higher, typically between 6 and 9 per 1,000. Both prevalence and incidence are higher in low-income regions. The annual incidence of epilepsy (the rate of new diagnoses each year) is estimated at 50 to 70 new cases per 100,000 people globally, based on population studies. Epilepsy is responsible for an estimated 13 million disability-adjusted life years (DALYs) worldwide each year, with the majority of this burden falling on individuals in low-resource settings where access to diagnosis and treatment remains limited. ==History==

of an antique bust The oldest medical records show that epilepsy has been affecting people at least since the beginning of recorded history. Throughout ancient history, the condition was thought to be of a spiritual cause. this definition was carried forward into the Ayurvedic text of Charaka Samhita (). The ancient Greeks had contradictory views of the condition. They thought of epilepsy as a form of spiritual possession, but also associated the condition with genius and the divine. One of the names they gave to it was the sacred disease (). Epilepsy appears in Greek mythology: it is associated with the Moon goddesses Selene and Artemis, who afflicted those who upset them. The Greeks thought that important figures such as Julius Caesar and Hercules had the condition. In Ancient Rome people did not eat or drink with the same pottery as that used by someone who was affected. People of the time would spit on their chest believing that this would keep the problem from affecting them. Occasionally a spinning potter's wheel was used, perhaps a reference to photosensitive epilepsy. In most cultures, persons with epilepsy have been stigmatized, shunned, or even imprisoned. As late as in the second half of the 20th century, in Tanzania and other parts of Africa epilepsy was associated with possession by evil spirits, witchcraft, or poisoning and was believed by many to be contagious. In the Salpêtrière, the birthplace of modern neurology, Jean-Martin Charcot found people with epilepsy side by side with the mentally ill, those with chronic syphilis, and the criminally insane. In Ancient Rome, epilepsy was known as the or 'disease of the assembly hall' and was seen as a curse from the gods. In northern Italy, epilepsy was traditionally known as Saint Valentine's malady. In at least the 1840s in the United States of America, epilepsy was known as the falling sickness or the falling fits, and was considered a form of medical insanity. Around the same time period, epilepsy was known in France as the , , , , and . The first modern treatment, phenobarbital, was developed in 1912, with phenytoin coming into use in 1938. ==Society and culture==

Beyond its medical impact, epilepsy is associated with social and cultural implications that vary across regions and contexts, including social stigma, legal restrictions, economic disadvantage, barriers to education and unemployment. A large treatment gap persists in many countries, particularly in low- and middle-income settings. Stigma Social stigma is commonly experienced by people with epilepsy worldwide. Misconceptions about the condition, including beliefs that it is contagious, a form of madness, or caused by supernatural forces, persist in many communities. In parts of Africa, including Tanzania and Uganda, epilepsy is sometimes associated with spirit possession, witchcraft, poisoning and is incorrectly believed to be contagious. Similar stigmatizing beliefs have been reported in other regions, such as India and China, where epilepsy may be cited as grounds for denying marriage. Negative perceptions of epilepsy can also affect educational opportunities and academic outcomes. In adulthood, stigma can also result in reduced employment opportunities and workplace discrimination. Adults with epilepsy are more likely to be unemployed or underemployed than the general population. Economic impact Epilepsy is associated with economic burden at both the individual and societal levels. In many countries, especially those with limited health infrastructure, individuals with epilepsy and their families often bear the majority of healthcare expenses out of pocket. A 2021 modeling study estimated the total global cost of epilepsy at approximately $119.27 billion annually, based on per capita cost projections applied to an estimated 52.51 million people living with epilepsy worldwide, while accounting for the treatment gap. The treatment gap, referring to the proportion of people with epilepsy who do not receive appropriate care, is high in low- and middle-income countries. Seizures result in direct economic costs of about one billion dollars in the United States. Driving and legal restrictions Those with epilepsy are at about twice the risk of being involved in a motor vehicular collision and thus in many areas of the world are not allowed to drive or able to drive only if certain conditions are met. In some countries, physicians are required by law to report if a person has had a seizure to the licensing body while in others the requirement is only that they encourage the person in question to report it themselves. Those with epilepsy or seizures are typically denied a pilot license. In Canada if an individual has had no more than one seizure, they may be considered after five years for a limited license if all other testing is normal. Those with febrile seizures and drug related seizures may also be considered. Rarely, exceptions can be made for persons who have had an isolated seizure or febrile seizures and have remained free of seizures into adulthood without medication. In the United Kingdom, a full National Private Pilot Licence requires the same standards as a professional driver's license. This requires a period of ten years without seizures while off medications. Those who do not meet this requirement may acquire a restricted license if free from seizures for five years. In the United States, the Epilepsy Foundation is a national organization that works to increase the acceptance of those with the disorder, their ability to function in society and to promote research for a cure. The Epilepsy Foundation, some hospitals, and some individuals also run support groups in the United States. In Australia, the Epilepsy Foundation provides support, delivers education and training and funds research for people living with epilepsy. International Epilepsy Day (World Epilepsy Day) began in 2015 and occurs on the second Monday in February. Purple Day, a different world-wide epilepsy awareness day for epilepsy, was initiated by a nine-year-old Canadian named Cassidy Megan in 2008, and is every year on 26 March. ==Research directions==

Epilepsy research spans the investigation of seizure mechanisms, improvements in diagnosis, and the development of new treatments, including efforts to understand and prevent epileptogenesis. Animal models Animal models are widely used in epilepsy research for studying epileptogenesis, seizure mechanisms, disease progression and potential treatments. Rodents are most commonly used, with models based on chemical induction (e.g. kainic acid, pilocarpine), electrical stimulation (e.g. kindling), genetic mutations and others. Other species, including zebrafish, dogs, and non-human primates, are also employed to capture features not easily replicated in rodents, such as complex behaviors or chronic seizure patterns. For example, recent preclinical work has shown that the experimental compound BICS01 can reversibly suppress epileptiform bursting in a high‑potassium hippocampal slice model. However, different animal models can yield divergent results in antiseizure drug screening, and it did not protect against seizures in the pentylenetetrazol (PTZ) mouse model. Genetics and molecular research Research on the genetic causes of epilepsy has clarified disease mechanisms and carries direct therapeutic implications. Mutations in genes affecting ion channels, synaptic transmission, and mTOR signaling pathways have been linked to epilepsy syndromes, and molecular studies also support the development of targeted therapies. Variations within the sodium channel SCN3A, and Na+/K+,ATPase (ATP1A3), has been implicated some of earliest onset epilepsies with cortical malformations. Epileptogenesis and biomarkers Understanding how epilepsy develops (epileptogenesis) is a major focus of current research, particularly in identifying biomarkers that predict who is at risk. EEG patterns, neuroimaging features, and molecular signals in blood or cerebrospinal fluid are being investigated as early indicators. No validated biomarker is yet in clinical use. Antiseizure drug development The development of new antiseizure medications remains a priority, especially for people with drug-resistant epilepsy. For example, research targets compounds with novel mechanisms of action, while pharmacogenomic studies aim to personalize drug selection based on individual genetic profiles. Cannabinoids and neurosteroids are also under investigation for specific syndromes and seizure types. Seizure prediction The unpredictability of seizures is a major concern for many people with epilepsy, and seizure prediction has been a longstanding focus of research. Early efforts were limited by small datasets and inconsistent results; however, advances in computational modeling, long-term EEG recording, and machine learning have led to renewed interest in the field. Public EEG databases and algorithm competitions have helped standardize evaluation and fostered the development of more accurate methods. In one clinical trial, prospective seizure prediction using intracranial EEG was achieved in a small group of participants. Current approaches often integrate network models of brain activity, multimodal data sources and closed-loop systems capable of both detecting and responding to pre-ictal changes. Remote detection of seizures Seizure detection methods based on scalp EEG present practical challenges in home and residential settings, as they require professional installation and maintenance of electrodes. Wearable devices incorporating three-dimensional accelerometers offer an alternative and have shown reliable performance; however, their effectiveness depends on correct placement, regular charging, and user compliance, which may limit their suitability for certain patient populations. Bed-based sensing systems, such as pressure or movement detectors integrated into mattresses, have also been explored, although their accuracy may vary depending on body position and the direction of seizure-related movements. In general, these approaches capture motion from a limited number of spatial locations. This has motivated the development of automated video-analysis methods, although many proposed techniques have not yet demonstrated consistent performance for real-time seizure alerting. An optical-flow-based automated approach reconstructs global movement parameters from video sequences, enabling the analysis of overall body motion rather than relying on localized movement signals. By performing the computationally intensive motion reconstruction as a single processing step, the resulting global motion descriptors can then be used by specialized detection modules to identify adverse events, including convulsive seizures, falls, apnea, and potential postictal cardiorespiratory compromise. Such systems have been described as operational and are undergoing evaluation in clinical and home-monitoring scenarios. Mechanistic modeling and alternative pathways Mathematical and computational models are increasingly used to simulate the neural dynamics underlying seizures. Reductionist models such as the Epileptor use ordinary differential equations to replicate interictal and ictal discharges observed in experimental data. More detailed versions, including the Epileptor-2, incorporate physiological variables such as ion concentrations and synaptic resource availability. These models suggest that fluctuations in extracellular potassium and intracellular sodium levels may play a role in the emergence and termination of seizures. Potential future therapies Several novel therapeutic strategies are under investigation for epilepsy. Gene therapy is being studied in some types of epilepsy. Medications that alter immune function, such as intravenous immunoglobulins, may reduce the frequency of seizures when including in normal care as an add-on therapy; however, further research is required to determine whether these medications are very well tolerated in children and in adults with epilepsy. Noninvasive stereotactic radiosurgery is, , being compared to standard surgery for certain types of epilepsy. ==Other animals==

Epilepsy has also been documented in several animal species, particularly dogs and cats. Veterinary treatments often use similar antiepileptic drugs, such as phenobarbital or levetiracetam. In horses, diagnosis can be challenging, especially in focal seizures, and such conditions as juvenile idiopathic epilepsy have been reported in foals. == See also ==